SCHEMBL10106344

SCHEMBL10106344

O=Cc1ccc(O)c(C(c2cccc(Cl)c2)c2cc(C=O)ccc2O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 1/20 0.43
PTGS2 P35354 1/20 0.43
TTR P02766 1/20 0.40
ERN1 O75460 1/20 0.40
ALDH1A1 P00352 4/20 0.38
ACP3 P15309 1/20 0.38
HPGD P15428 3/20 0.37
ALDH5A1 P51649 2/20 0.37
ABAT P80404 2/20 0.37
TRIM24 O15164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TRIM33 Q9UPN9 1/20 0.37
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
ALOX5 P09917 1/20 0.36
HSD17B10 Q99714 1/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10106351 0.84 ALDH1A1 (0.51) RAB9AKDM4EPTGS2ERN1ALDH1A1
SCHEMBL7074379 0.83 KDM4E (0.50) RAB9AKDM4EPTGS2ALDH1A1HPGD
SCHEMBL10106319 0.82 ALDH1A1 (0.45) RAB9AKDM4EPTGS2ALDH1A1HPGD
SCHEMBL10106334 0.82 KDM4E (0.43) RAB9AKDM4EPTGS2ALDH1A1ACP3
SCHEMBL10144995 0.81 ACMSD (0.39) RAB9AKDM4EPTGS2ALDH1A1HPGD
SCHEMBL10106338 0.79 ALDH1A1 (0.48) RAB9AKDM4EPTGS2TTRERN1
SCHEMBL10106416 0.79 KDM4E (0.40) RAB9AKDM4EPTGS2ALDH1A1HPGD
SCHEMBL10106339 0.79 ALDH1A1 (0.47) TTRALDH1A1HPGDALDH5A1ABAT
SCHEMBL10106450 0.79 ALDH1A1 (0.40) RAB9AKDM4EPTGS2ALDH1A1HPGD
SCHEMBL10106385 0.79 ALDH1A1 (0.44) RAB9AKDM4EPTGS2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES TTPA, HAVCR2, PML RAB9A 2880/4885KDM4E 4428/4885PTGS2 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.